Home > Resources > Whitepapers > Biodegradation – Putting Biology to Work

Biodegradation – Putting Biology to Work

October 7, 2015

Biodegradation is the action of microorganisms to decompose a substance into its constituent elements or new compounds. This is the key process by which biodegradable plastics are broken down in the environment.

Spotlight

CoHealth (Formerly Dash MD)

CoHealth is a patient access platform delivered to patients in any healthcare setting. We capture patient attention through our personal health manager by partnering with health providers to create customized, digital care pathways for a variety of health related conditions. We then use patient attention to drive insights and value to our partners to promote organizational efficiencies and strategic decision making.

OTHER WHITEPAPERS

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

BIOPHARMACEUTICAL INDUSTRY AND INTERRELATED BIOTECHNOLOGY ORGANIZATIONS

whitePaper | November 21, 2019

Our Accounting and Finance team has published an overview of the accounting and finance challenges facing the Biopharmaceutical industry and interrelated Biotechnology organizations.

Synthetic Biology Biotechnology & AgTech

whitePaper | June 8, 2022

For nearly two decades, the Future Today Institute has meticulously researched macro forces of change and the emerging trends that result. Our focus: understanding how these forces and trends will shape our futures.

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.

A New Generation of Cancer Immunotherapies

whitePaper | June 9, 2022

Despite recent progress in fighting cancer the sad reality is that it remains a leading cause of morbidity and mortality. Some of the most promising new treatments have emerged from the convergence of the oncology and immunology fields.